| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Krishnan Suma | President, R&D, Director, 10%+ Owner | C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH | /s/ Suma M. Krishnan | 2025-12-05 | 0001298711 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | KRYS | Common Stock | Sale | -$150K | -700 | -0.05% | $214.25 | 1.44M | Dec 4, 2025 | Direct | F1, F2 |
| transaction | KRYS | Common Stock | Sale | -$129K | -600 | -0.04% | $215.49 | 1.44M | Dec 4, 2025 | Direct | F1, F3 |
| transaction | KRYS | Common Stock | Sale | -$304K | -1.4K | -0.1% | $216.97 | 1.44M | Dec 4, 2025 | Direct | F1, F4 |
| transaction | KRYS | Common Stock | Sale | -$786K | -3.59K | -0.25% | $218.83 | 1.43M | Dec 4, 2025 | Direct | F1, F5 |
| transaction | KRYS | Common Stock | Sale | -$1.19M | -5.42K | -0.38% | $219.68 | 1.43M | Dec 4, 2025 | Direct | F1, F6 |
| transaction | KRYS | Common Stock | Sale | -$579K | -2.63K | -0.18% | $220.52 | 1.42M | Dec 4, 2025 | Direct | F1, F7 |
| transaction | KRYS | Common Stock | Sale | -$2.32M | -10.5K | -0.73% | $221.82 | 1.41M | Dec 4, 2025 | Direct | F1, F8 |
| transaction | KRYS | Common Stock | Sale | -$44.5K | -200 | -0.01% | $222.38 | 1.41M | Dec 4, 2025 | Direct | F1, F9 |
| transaction | KRYS | Common Stock | Sale | -$205K | -956 | -0.06% | $214.28 | 1.51M | Dec 4, 2025 | By Spouse | F11, F12, F13 |
| transaction | KRYS | Common Stock | Sale | -$74.1K | -344 | -0.02% | $215.48 | 1.51M | Dec 4, 2025 | By Spouse | F11, F13, F14 |
| transaction | KRYS | Common Stock | Sale | -$347K | -1.6K | -0.11% | $217.04 | 1.51M | Dec 4, 2025 | By Spouse | F11, F13, F15 |
| transaction | KRYS | Common Stock | Sale | -$564K | -2.58K | -0.17% | $218.72 | 1.5M | Dec 4, 2025 | By Spouse | F11, F13, F16 |
| transaction | KRYS | Common Stock | Sale | -$1.25M | -5.69K | -0.38% | $219.53 | 1.5M | Dec 4, 2025 | By Spouse | F11, F13, F17 |
| transaction | KRYS | Common Stock | Sale | -$578K | -2.63K | -0.18% | $220.34 | 1.49M | Dec 4, 2025 | By Spouse | F11, F13, F18 |
| transaction | KRYS | Common Stock | Sale | -$2.33M | -10.5K | -0.7% | $221.78 | 1.48M | Dec 4, 2025 | By Spouse | F11, F13, F19 |
| transaction | KRYS | Common Stock | Sale | -$156K | -700 | -0.05% | $222.20 | 1.48M | Dec 4, 2025 | By Spouse | F11, F13, F20 |
| transaction | KRYS | Common Stock | Gift | $0 | -5K | -0.34% | $0.00 | 1.48M | Dec 5, 2025 | By Spouse | F13, F21 |
| holding | KRYS | Common Stock | 90K | Dec 4, 2025 | By SMK Trust | ||||||
| holding | KRYS | Common Stock | 50K | Dec 4, 2025 | By Krishnan Family Trust | F10 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025. The Rule 10b5-1 trading plan started on December 4, 2025 and will terminate on December 4, 2026, or earlier upon completion of the sale of the maximum number of shares of Common Stock subject to the Rule 10b5-1 trading plan. |
| F2 | The transaction was executed in multiple trades ranging from $213.87 to $214.68. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| F3 | The transaction was executed in multiple trades ranging from $215.34 to $215.80. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| F4 | The transaction was executed in multiple trades ranging from $216.60 to $217.53. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| F5 | The transaction was executed in multiple trades ranging from $218.21 to $219.20. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| F6 | The transaction was executed in multiple trades ranging from $219.21 to $220.20. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| F7 | The transaction was executed in multiple trades ranging from $220.21 to $221.18. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| F8 | The transaction was executed in multiple trades ranging from $221.21 to $222.15. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| F9 | The transaction was executed in multiple trades ranging from $222.34 to $222.41. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| F10 | Directly beneficially owned by the Krishnan Family Trust. The reporting person and her spouse are each joint beneficial owners of the trust with joint voting and investment control. |
| F11 | The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person's spouse, Krish S. Krishnan, on September 4, 2025. The Rule 10b5-1 trading plan started on December 4, 2025 and will terminate on December 4, 2026, or earlier upon completion of the sale of the maximum number of shares of Common Stock subject to the Rule 10b5-1 trading plan. |
| F12 | The transaction was executed in multiple trades ranging from $213.93 to $214.67. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| F13 | Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person. |
| F14 | The transaction was executed in multiple trades ranging from $214.99 to $215.80. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| F15 | The transaction was executed in multiple trades ranging from $216.73 to $217.63. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| F16 | The transaction was executed in multiple trades ranging from $218.11 to $219.07. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| F17 | The transaction was executed in multiple trades ranging from $219.14 to $220.13. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| F18 | The transaction was executed in multiple trades ranging from $220.14 to $221.11. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| F19 | The transaction was executed in multiple trades ranging from $221.14 to $222.11. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| F20 | The transaction was executed in multiple trades ranging from $222.14 to $222.30. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| F21 | Represents a bona fide gift of Krystal Biotech, Inc.'s Common Stock to a charitable donor-advised fund. |